发布求助
文献互助 智能选刊 最新文献

Clinical Lymphoma, Myeloma & Leukemia最新文献

筛选
英文 中文
OA-29 Mezigdomide (MEZI), Tazemetostat (TAZ), and Dexamethasone (DEX) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results From the CA057-003 Trial OA-29 Mezigdomide (MEZI)、Tazemetostat (TAZ) 和地塞米松 (DEX) 用于复发性/难治性多发性骨髓瘤 (RRMM) 患者 (pts)：CA057-003 试验的初步结果
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01870-6
{"title":"OA-29 Mezigdomide (MEZI), Tazemetostat (TAZ), and Dexamethasone (DEX) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results From the CA057-003 Trial","authors":"","doi":"10.1016/S2152-2650(24)01870-6","DOIUrl":"10.1016/S2152-2650(24)01870-6","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-026 Combined GPRC5D and BCMA-targeted T-cell Redirecting Therapy in the Treatment of RRMM P-026 GPRC5D和BCMA靶向T细胞重定向疗法联合治疗RRMM
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01929-3
{"title":"P-026 Combined GPRC5D and BCMA-targeted T-cell Redirecting Therapy in the Treatment of RRMM","authors":"","doi":"10.1016/S2152-2650(24)01929-3","DOIUrl":"10.1016/S2152-2650(24)01929-3","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-04 A Phase 1 Study of P-BCMA- ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM) OA-04 P-BCMA- ALLO1治疗复发性/难治性多发性骨髓瘤（RRMM）的非病毒异基因BCMA定向CAR-T 1期研究
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01845-7
{"title":"OA-04 A Phase 1 Study of P-BCMA- ALLO1, a Non-viral, Allogeneic BCMA Directed CAR-T in Relapsed/Refractory Multiple Myeloma (RRMM)","authors":"","doi":"10.1016/S2152-2650(24)01845-7","DOIUrl":"10.1016/S2152-2650(24)01845-7","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-019 Cytotoxic CD4+ T cells are major drivers of side effects and response after chimeric antigen receptor T cells against BCMA P-019 细胞毒性 CD4+ T 细胞是嵌合抗原受体 T 细胞抗 BCMA 副作用和反应的主要驱动因素
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01922-0
{"title":"P-019 Cytotoxic CD4+ T cells are major drivers of side effects and response after chimeric antigen receptor T cells against BCMA","authors":"","doi":"10.1016/S2152-2650(24)01922-0","DOIUrl":"10.1016/S2152-2650(24)01922-0","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-031 Phase I Study to Evaluate Cellular Immunotherapy Using CS-1 Targeting Autologous CAR T Cells in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) P-031 评估使用 CS-1 靶向自体 CAR T 细胞对复发性和难治性多发性骨髓瘤 (RRMM) 患者进行细胞免疫治疗的 I 期研究
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01934-7
{"title":"P-031 Phase I Study to Evaluate Cellular Immunotherapy Using CS-1 Targeting Autologous CAR T Cells in Patients with Relapsed and Refractory Multiple Myeloma (RRMM)","authors":"","doi":"10.1016/S2152-2650(24)01934-7","DOIUrl":"10.1016/S2152-2650(24)01934-7","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-56 Single Cell Analyses of Bone Marrow Immune Microenvironment in RRMM Subjects Treated with MEK1/2 Inhibitors Reveal IRF1-Mediated IFN/PDL1 Signaling Axes OA-56 对接受MEK1/2抑制剂治疗的RRMM受试者骨髓免疫微环境的单细胞分析揭示了IRF1介导的IFN/PDL1信号轴
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01897-4
{"title":"OA-56 Single Cell Analyses of Bone Marrow Immune Microenvironment in RRMM Subjects Treated with MEK1/2 Inhibitors Reveal IRF1-Mediated IFN/PDL1 Signaling Axes","authors":"","doi":"10.1016/S2152-2650(24)01897-4","DOIUrl":"10.1016/S2152-2650(24)01897-4","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-009 Digital Remote Patient Monitoring for Cytokine Release Syndrome in ABBV-383 Treatment: Methodology and Setup P-009 ABBV-383 治疗中细胞因子释放综合征的数字远程患者监测：方法与设置
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01912-8
{"title":"P-009 Digital Remote Patient Monitoring for Cytokine Release Syndrome in ABBV-383 Treatment: Methodology and Setup","authors":"","doi":"10.1016/S2152-2650(24)01912-8","DOIUrl":"10.1016/S2152-2650(24)01912-8","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-25 Impact of Clonal Hematopoiesis on the Carcinogenic Process of Multiple Myeloma OA-25 克隆造血对多发性骨髓瘤致癌过程的影响
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01866-4
{"title":"OA-25 Impact of Clonal Hematopoiesis on the Carcinogenic Process of Multiple Myeloma","authors":"","doi":"10.1016/S2152-2650(24)01866-4","DOIUrl":"10.1016/S2152-2650(24)01866-4","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
P-006 Differential Neutrophil Trajectory in Duffy-Null Multiple Myeloma Patients Mimics Delayed Neutrophil Recovery Following BCMA-directed CART P-006 Duffy-null多发性骨髓瘤患者的中性粒细胞轨迹差异模拟了BCMA指导的CART治疗后中性粒细胞的延迟恢复
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01909-8
{"title":"P-006 Differential Neutrophil Trajectory in Duffy-Null Multiple Myeloma Patients Mimics Delayed Neutrophil Recovery Following BCMA-directed CART","authors":"","doi":"10.1016/S2152-2650(24)01909-8","DOIUrl":"10.1016/S2152-2650(24)01909-8","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142310834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OA-20 A New Circulating Tumor Cell-Based Prognostic System To Refine Patient Stratification Status of Newly Diagnosed Multiple Myeloma Patients OA-20 基于循环肿瘤细胞的新预后系统，用于完善新诊断多发性骨髓瘤患者的分层状况
IF 2.7 4区 医学
Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI: 10.1016/S2152-2650(24)01861-5
{"title":"OA-20 A New Circulating Tumor Cell-Based Prognostic System To Refine Patient Stratification Status of Newly Diagnosed Multiple Myeloma Patients","authors":"","doi":"10.1016/S2152-2650(24)01861-5","DOIUrl":"10.1016/S2152-2650(24)01861-5","url":null,"abstract":"","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":null,"pages":null},"PeriodicalIF":2.7,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信